Fleur Schaper1, Karina de Leeuw1, Gerda Horst1, Hendrika Bootsma1, Pieter C Limburg2, Peter Heeringa3, Marc Bijl4, Johanna Westra5. 1. Departments of Rheumatology & Clinical Immunology. 2. Laboratory Medicine. 3. Pathology & Medical Biology, University Medical Center Groningen, University of Groningen. 4. Department of Internal Medicine and Rheumatology, Martini Hospital, Groningen, The Netherlands. 5. Departments of Rheumatology & Clinical Immunology johanna.westra@umcg.nl.
Abstract
OBJECTIVES: Decreased phagocytosis of apoptotic cells plays an important role in the pathogenesis of SLE. This can lead to secondary necrosis and release of nuclear proteins, such as high mobility group box 1 (HMGB1). We hypothesized that increased HMGB1 levels, as present in SLE, skew macrophage differentiation towards M1-like phenotypes and thereby diminish uptake of apoptotic cells. The aim of this study was to investigate the effect of HMGB1 on macrophage polarization and on phagocytic capacity of differentiated macrophages. METHODS: SLE patients with quiescent disease (SLEDAI ⩽4) and healthy controls (HCs) were included. Monocytes and differentiated M1 and M2 macrophages were assessed for expression of M1 and M2 markers and for phagocytic capacity. HMGB1 was added during differentiation and during phagocytosis. RESULTS: Expression of CD86 (M1) was not different, whereas CD163 (M2) was significantly lower on SLE monocytes. After differentiation, no differences regarding surface receptor expression and phagocytic capacity were observed between M1 and M2 macrophages from SLE patients and HCs. Addition of HMGB1 during M2 differentiation resulted in high IL-6 and TNF-α mRNA expression and reduced phagocytic capacity of apoptotic cells. Furthermore, adding HMGB1 to apoptotic Jurkat cells diminished phagocytosis of these cells. CONCLUSION: Circulating monocytes from SLE patients display an M1-like phenotype compared with HCs, but in vitro differentiation abolishes this difference. HMGB1 skews differentiation of M2-like macrophages towards an M1-like phenotype and, subsequently, reduces phagocytosis of apoptotic cells. These data imply that the phenotype of monocytes or macrophages is determined by their environment, such as the presence of cytokines and HMGB1.
OBJECTIVES: Decreased phagocytosis of apoptotic cells plays an important role in the pathogenesis of SLE. This can lead to secondary necrosis and release of nuclear proteins, such as high mobility group box 1 (HMGB1). We hypothesized that increased HMGB1 levels, as present in SLE, skew macrophage differentiation towards M1-like phenotypes and thereby diminish uptake of apoptotic cells. The aim of this study was to investigate the effect of HMGB1 on macrophage polarization and on phagocytic capacity of differentiated macrophages. METHODS:SLEpatients with quiescent disease (SLEDAI ⩽4) and healthy controls (HCs) were included. Monocytes and differentiated M1 and M2 macrophages were assessed for expression of M1 and M2 markers and for phagocytic capacity. HMGB1 was added during differentiation and during phagocytosis. RESULTS: Expression of CD86 (M1) was not different, whereas CD163 (M2) was significantly lower on SLE monocytes. After differentiation, no differences regarding surface receptor expression and phagocytic capacity were observed between M1 and M2 macrophages from SLEpatients and HCs. Addition of HMGB1 during M2 differentiation resulted in high IL-6 and TNF-α mRNA expression and reduced phagocytic capacity of apoptotic cells. Furthermore, adding HMGB1 to apoptotic Jurkat cells diminished phagocytosis of these cells. CONCLUSION: Circulating monocytes from SLEpatients display an M1-like phenotype compared with HCs, but in vitro differentiation abolishes this difference. HMGB1 skews differentiation of M2-like macrophages towards an M1-like phenotype and, subsequently, reduces phagocytosis of apoptotic cells. These data imply that the phenotype of monocytes or macrophages is determined by their environment, such as the presence of cytokines and HMGB1.
Authors: Qing Lin; Chunling Fan; John T Skinner; Elizabeth N Hunter; Andrew A Macdonald; Peter B Illei; Kazuyo Yamaji-Kegan; Roger A Johns Journal: J Immunol Date: 2019-10-14 Impact factor: 5.422
Authors: Melissa L Wilkinson; Elena Abramova; Changjiang Guo; James G Gow; Alexa Murray; Adolf Koudelka; Veronika Cechova; Bruce A Freeman; Andrew J Gow Journal: Toxicol Appl Pharmacol Date: 2020-09-12 Impact factor: 4.219
Authors: Charlotte Dahlem; Wei Xiong Siow; Maria Lopatniuk; William K F Tse; Sonja M Kessler; Susanne H Kirsch; Jessica Hoppstädter; Angelika M Vollmar; Rolf Müller; Andriy Luzhetskyy; Karin Bartel; Alexandra K Kiemer Journal: Cancers (Basel) Date: 2020-05-19 Impact factor: 6.639
Authors: Bernardo L Rapoport; Helen C Steel; Annette J Theron; Liezl Heyman; Teresa Smit; Yastira Ramdas; Ronald Anderson Journal: Cells Date: 2020-07-10 Impact factor: 6.600